At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 129 enrolled
Drug / intervention
Olopatadine HCL (Patanase) Nasal Spray, 0.6% +1 moredrug
Likely dose
Azelastine HCl (Astelin) Nasal Spray, 137 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
In Brief
A Phase 4 clinical trial evaluating Olopatadine HCL (Patanase) Nasal Spray, 0.6% and Azelastine HCl (Astelin) Nasal Spray, 137 mcg for Vasomotor Rhinitis. Completed, enrolled 129 participants across 1 site.
Detailed Summary
The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasomotor Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionNov 2009
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.8 years ago
Interventions
Olopatadine HCL (Patanase) Nasal Spray, 0.6%drug
2 sprays/ nostril BID
Azelastine HCl (Astelin) Nasal Spray, 137 mcgdrug
2 sprays/ nostril BID